Tue, April 26, 2022
Mon, April 25, 2022
Sun, April 24, 2022
Fri, April 22, 2022
Thu, April 21, 2022
Wed, April 20, 2022

Do Kim Maintained (VRTX) at Hold with Increased Target to $249 on, Apr 22nd, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-increased-target-to-249-on-apr-22nd-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Do Kim of Piper Sandler, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold with Increased Target from $245 to $249 on, Apr 22nd, 2022.

Do has made no other calls on VRTX in the last 4 months.



There are 9 other peers that have a rating on VRTX. Out of the 9 peers that are also analyzing VRTX, 2 agree with Do's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $274 on, Wednesday, April 6th, 2022
  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $222 on, Thursday, January 27th, 2022


These are the ratings of the 7 analyists that currently disagree with Do


  • Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $325 on, Wednesday, April 13th, 2022
  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $300 on, Tuesday, April 5th, 2022
  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $350 on, Monday, April 4th, 2022
  • Liisa Bayko of "Evercore ISI Group" Maintained at Buy with Increased Target to $278 on, Friday, April 1st, 2022
  • Brian Skorney of "Baird" Maintained at Buy and Held Target at $240 on, Wednesday, March 23rd, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Thursday, January 27th, 2022
  • Evan Seigerman of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $274 on, Thursday, January 20th, 2022

Publication Contributing Sources